Mukul Gupta, MD
Hematology & Oncology · Santa Barbara, CANPI 1295843738
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,040 of the $11,407 with a category attached, or 61.7%. 37 manufacturers reported payments, led by Gilead at 52.1% of the total. Reporting peaked in 2022 at $7,976 and has fallen 95.3% since, to $372 in 2025.
Across 115 payments — averaging $99.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$6K
- EMD Serono, Inc.$2K
- Bristol Myers Squibb$1K
- E.r. Squibb & Sons, L.L.C.$272
- AbbVie$231
- AstraZeneca$203
- plus $2K from 31 others
Across 523 payments — averaging $3121.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$472K
- Merck$317K
- Biontech SE$207K
- Exelixis Inc.$145K
- AstraZeneca$97K
- Amgen$81K
- plus $314K from 10 others
What the payments were for
- Consulting fees$7,04062%
- Travel & lodging$1,33612%
- Food & beverage$2,94626%
- Education$691%
- Other$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 7 | $5,947 |
| EMD Serono, Inc. | 12 | $1,724 |
| Bristol Myers Squibb | 4 | $1,115 |
| E.r. Squibb & Sons, L.L.C. | 3 | $272 |
| AbbVie | 7 | $231 |
| AstraZeneca(2 entities) | 10 | $203 |
| Johnson & Johnson | 11 | $201 |
| GSK | 3 | $171 |
| Pfizer | 6 | $141 |
| Novartis | 6 | $136 |
| Jazz Pharmaceuticals Inc. | 1 | $117 |
| Adaptive Biotechnologies Corporation | 4 | $111 |
| Seagen Inc. | 5 | $106 |
| Sumitomo Pharma America, Inc. | 1 | $106 |
| Tesaro, Inc. | 1 | $98 |
| Sanofi | 1 | $80 |
| Astellas Pharma US Inc | 4 | $77 |
| Incyte Corporation | 3 | $64 |
| ADC Therapeutics America, Inc. | 3 | $54 |
| Beigene USA, Inc. | 3 | $53 |
| Agios Pharmaceuticals, Inc. | 2 | $42 |
| Lilly USA, LLC | 2 | $36 |
| Portola Pharmaceuticals, LLC | 1 | $32 |
| Merck | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Rigel Pharmaceuticals, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| EUSA Pharma (US) LLC | 1 | $24 |
| Acrotech Biopharma Inc. | 1 | $23 |
| Genmab U.S., Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Flowonix Medical Incorporated | 1 | $19 |
| Melinta Therapeutics, LLC | 1 | $18 |
| Welch Allyn | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Bayer | 1 | $15 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,407 in reported general payments places this provider in the 70th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 18 | $390,739 |
| RevlimidLenalidomide | 18 | $328,659 |
| TasignaNilotinib Hcl | 14 | $276,996 |
| NubeqaDarolutamide | 18 | $245,968 |
| BrukinsaZanubrutinib | 18 | $228,671 |
| IbrancePalbociclib | 15 | $226,216 |
| LynparzaOlaparib | 12 | $198,650 |
| Abiraterone Acetate | 43 | $131,796 |
| Lenalidomide | 11 | $66,946 |
| CreonLipase/Protease/Amylase | 19 | $65,945 |
| EliquisApixaban | 82 | $65,537 |
| XareltoRivaroxaban | 29 | $39,264 |
| Anastrozole | 62 | $1,738 |
| ValacyclovirValacyclovir Hcl | 18 | $1,129 |
| Acyclovir | 23 | $811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $272 | $390,73918 claims |
| Bristol Myers SquibbRevlimid | $1,115 | $328,65918 claims |
| PfizerIbrance, Eliquis | $141 | $291,75397 claims |
| NovartisTasigna | $136 | $276,99614 claims |
| BayerNubeqa | $15 | $245,96818 claims |
| Beigene USA, Inc.Brukinsa | $53 | $228,67118 claims |
| AstraZenecaLynparza | $203 | $198,65012 claims |
| AbbVieCreon | $231 | $65,94519 claims |
| Johnson & JohnsonXarelto | $201 | $39,26429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Santa Barbara
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.